1800-272-662
Shopping Cart 0
countryflagAU
Login

Neurotech International Ltd

Healthcare AU NTI

0.012AUD
0.0005(4.35%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.010.04
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap14.91M
  • Volume2969230
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.98740M
  • Revenue TTM7.07M
  • Revenue Per Share TTM0.007
  • Gross Profit TTM 8.55M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -10.59886M -8.24462M -7.79194M -3.36224M -7.43063M
Minority interest - - - - -
Net income -10.59886M -5.06925M -7.79194M -3.36224M -7.43063M
Selling general administrative 1.21M 2.38M 1.62M 0.62M 1.63M
Selling and marketing expenses 0.00464M 0.00038M 0.01M 0.01M 0.01M
Gross profit 2.44M -0.00587M 0.00596M 0.00424M 0.23M
Reconciled depreciation 0.00029M 0.00058M 0.00174M 0.00059M -
Ebit -10.73595M -8.24462M -9.04907M -3.36087M -14.89631M
Ebitda -10.73566M -8.24403M -9.04733M -3.36028M -7.44809M
Depreciation and amortization 0.00029M 0.00058M 0.00174M 0.00059M 7.45M
Non operating income net other - - - - -
Operating income -11.08822M -8.76075M -7.85150M -3.36136M -7.44822M
Other operating expenses 13.53M 8.76M -8.98643M -3.90039M -7.63542M
Interest expense - - - 0.00137M 0.00171M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.14M 0.16M 0.06M 0.00049M 0.00014M
Net interest income 0.14M 0.16M 0.06M -0.00088M -0.00157M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -3.17537M -0.05956M 0.57M -7.44652M
Total revenue 2.44M 0.00196M 0.00596M 0.04M 0.21M
Total operating expenses 13.53M 8.75M 9.06M 3.93M 7.67M
Cost of revenue 0.00029M 0.00783M 0.00000M 0.03M -0.02034M
Total other income expense net 0.49M 0.52M 1.20M 0.57M 0.02M
Discontinued operations - - - - -
Net income from continuing ops -10.59886M -5.06925M -7.79194M -3.36224M -7.43063M
Net income applicable to common shares -10.59886M -5.06925M -7.79194M -3.36224M -7.43063M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 3.24M 12.21M 5.31M 2.02M 5.01M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.27M 0.02M 0.02M 0.04M
Total liab 0.29M 0.31M 1.35M 0.59M 1.14M
Total stockholder equity 2.95M 11.90M 3.96M 1.43M 3.86M
Deferred long term liab - - - - -
Other current liab - 0.04M 0.06M 0.07M 0.03M
Common stock - 46.73M 34.35M 25.78M 25.75M
Capital stock 48.91M - 34.35M 25.78M 25.75M
Retained earnings -52.15615M -41.55730M -36.42804M -28.69610M -25.33386M
Other liab - - - - 0.80M
Good will - - - - -
Other assets - - - - -0.00262M
Cash 3.03M 2.11M 5.03M 1.90M 4.83M
Cash and equivalents - - - - 4.83M
Total current liabilities 0.29M 0.31M 1.35M 0.59M 0.35M
Current deferred revenue - - - - -
Net debt - -2.11048M -5.02579M -1.89543M -4.82737M
Short term debt - - 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - 0.07M 4.35M -0.41651M
Property plant equipment - - 0.00087M 0.00262M 0.00000M
Total current assets 3.24M 12.21M 5.31M 2.02M 5.01M
Long term investments - - - - -
Net tangible assets - - 3.96M 1.43M 3.86M
Short term investments - 9.52M 2.02M 0.01M -
Net receivables - 0.32M 0.26M 0.10M 0.14M
Long term debt - - - - -
Inventory - - 0.00778M 0.00720M 0.00720M
Accounts payable 0.22M 0.28M 1.29M 0.52M 0.32M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 6.72M 6.04M 4.35M 3.44M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00000M -0.00087M -0.00262M -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00029M 0.00087M 0.00262M 0.00262M
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.00000M - - -0.00320M -
Change to liabilities - - 0.75M 0.24M 0.47M
Total cashflows from investing activities - - 0.00000M -0.00320M -0.00320M
Net borrowings - - - - -0.04658M
Total cash from financing activities 0.43M 11.19M 9.45M 0.03M 7.13M
Change to operating activities - - 0.00142M 0.04M -0.00077M
Net income -10.59886M -5.06925M -7.79194M -3.36224M -7.43063M
Change in cash -8.59453M 6.60M 3.13M -2.93194M 4.82M
Begin period cash flow 11.63M 5.03M 1.90M 4.83M 0.01M
End period cash flow 3.03M 11.63M 5.03M 1.90M 4.83M
Total cash from operating activities -9.02405M -4.59529M -6.31696M -2.95513M -2.31653M
Issuance of capital stock 0.43M 11.19M 9.45M 0.03M 7.62M
Depreciation 0.00029M 0.00058M 0.00175M 0.00059M 0.00175M
Other cashflows from investing activities - -4.59529M - - -
Dividends paid - - - - -7.13077M
Change to inventory - 0.00778M -0.00058M -0.00720M -0.00720M
Change to account receivables 0.23M -0.06049M -0.15808M 0.04M -0.11682M
Sale purchase of stock - - 9.45M 0.03M -0.44348M
Other cashflows from financing activities - 0.00000M - -0.00320M -0.00320M
Change to netincome - - 0.88M 0.08M 4.76M
Capital expenditures 0.00000M 4.60M 0.00000M 0.00320M 0.00320M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.38M -1.70847M -0.15866M 0.04M -0.11682M
Stock based compensation 1.58M 2.18M 0.88M 0.08M 4.99M
Other non cash items -0.38381M 2.18M 1.47M 0.29M 0.24M
Free cash flow -9.02405M -4.59529M -6.31696M -2.95834M -2.31653M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NTI
Neurotech International Ltd		 0.0005 4.35% 0.01 - - 2.11 2.54 58071.91 -6.7445
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.

Neurotech International Ltd

55 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Alexandra Andrews Chief Operating Officer NA
Prof. Allan Cripps A.O., AO, B.Sc., Ph.D. Chief Scientist & Innovation and Director NA
Dr. Emanuela Russo Chief Scientific Officer & Member of Scientific Advisory Board NA
Mr. Gerald Quigley Director of PR & Director NA
Dr. Thomas Duthy M.B.A., Ph.D. Exec. Director NA
Mr. Peter James Lawrence Griffiths B.Sc. Chief Exec. Officer of AAT Research Ltd 1964
Ms. Erlyn Saromines Dawson A.C.I.S., ACIS, AGIA, B.Com., BCom., GradDipACG Company Sec. NA
Mr. Gerald Quigley Director of Public Relations & Director NA
Dr. Thomas Duthy M.B.A., Ph.D. Executive Director NA
Mr. Peter James Lawrence Griffiths B.Sc. Chief Executive Officer of AAT Research Ltd 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.